Effect of atorvastatin on the adverse events after middle cerebral artery stenting
10.3969/j.issn.1672-5921.2011.04.005
- Author:
Wei KE
1
Author Information
1. Department of Neurology
- Publication Type:Journal Article
- Keywords:
Atorvastatin;
Brain infarction;
Middle cerebral artery;
Stent
- From:
Chinese Journal of Cerebrovascular Diseases
2011;8(4):185-188
- CountryChina
- Language:Chinese
-
Abstract:
Objectives: To investigate the effect of atorvastatin on the adverse events after middle cerebral artery stenting. Methods: Twenty-four patients who successfully completed middle cerebral artery stenting (restenosis rate ≥ 70%) were randomly assigned to 2 groups; treatment group (taking atorvastatin 40 mg + plavix 75mg + aspirin enteric-coated tablet 300 mg, once a day) and control group (taking plavix 75mg + aspirin enteric-coated tablet 100 mg, once a day) (n = 12 in each group). The patients were followed up at 1, 3, 6, and 12 months after procedure. New adverse events (transient ischemic attack, cerebral infarction, restenosis, and reintervention) were recorded. Results: Compared with the control group, the blood lipid level and C-reactive protein level were decreased significantly at all time points in the treatment group (P < 0.05 or P < 0.01), except the LDL-C level at 1 month. The total incidence of adverse events in the treatment group was lower than that in the control group. There was statistically significant difference (P =0.00017); however, the C-reactive protein level was higher than that before procedure, and it was lower than that before procedure until 12 months. The blood lipid level after procedure was significantly lower than that before procedure in the treatment group. Conclusion: Atorvastatin treatment after middle cerebral artery stenting may effectively prevent the occurrence of adverse events after stenting.
